CO6721028A2 - Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina - Google Patents

Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina

Info

Publication number
CO6721028A2
CO6721028A2 CO13147309A CO13147309A CO6721028A2 CO 6721028 A2 CO6721028 A2 CO 6721028A2 CO 13147309 A CO13147309 A CO 13147309A CO 13147309 A CO13147309 A CO 13147309A CO 6721028 A2 CO6721028 A2 CO 6721028A2
Authority
CO
Colombia
Prior art keywords
synthesis
cyclopenta
isolation
trisodium salt
quinazoline
Prior art date
Application number
CO13147309A
Other languages
English (en)
Inventor
James Alan Kerschen
Alexander James Bridges
Milind D Choubal
Sean Mark Dalziel
Thomas Elliott Jacks
Andrew S Thompson
James Robert Zeller
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Publication of CO6721028A2 publication Critical patent/CO6721028A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/088—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing other elements, e.g. B, Si, As
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1896—Compounds having one or more Si-O-acyl linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

se proporciona 1- un nuevo método para la síntesis de L-glutamil-?- ácido D-glutámico y su uso en la síntesis de (2R)-((4S)-carboxi-4-(4, N-(((6S)-2-(hidroximetil)-4-oxo-3,4,7,8- tetrahidro-3H-ciclopenta[g] quinazolin-6-il)-N-(prop-2-inil)amino)benzamido) butanamido)pentanodioico. También se proporciona: 2- un método eficiente para el aislamiento y purificación de la sal trisódica del ácido arriba mencionado en una forma adecuada para almacena a largo plazo y su uso en una forma de dosificación parenteral.
CO13147309A 2010-12-22 2013-06-20 Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina CO6721028A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061459952P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
CO6721028A2 true CO6721028A2 (es) 2013-07-31

Family

ID=46314794

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13147309A CO6721028A2 (es) 2010-12-22 2013-06-20 Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina

Country Status (17)

Country Link
US (1) US9458188B2 (es)
EP (1) EP2655398B1 (es)
JP (1) JP2014513663A (es)
KR (1) KR20130132481A (es)
CN (1) CN103748106A (es)
AU (1) AU2011349551A1 (es)
BR (1) BR112013015600A2 (es)
CA (1) CA2819510A1 (es)
CO (1) CO6721028A2 (es)
DK (1) DK2655398T3 (es)
EA (1) EA201390635A1 (es)
HU (1) HUE028918T2 (es)
IL (1) IL226452A0 (es)
MX (1) MX2013007006A (es)
SG (1) SG191269A1 (es)
WO (1) WO2012087888A2 (es)
ZA (1) ZA201303821B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104151398A (zh) * 2014-08-06 2014-11-19 四川同晟氨基酸有限公司 一种合成以谷氨酸为首个氨基酸残基二肽的方法
GB201707864D0 (en) * 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment
CN107236021B (zh) * 2017-06-12 2020-12-01 湖北泓肽生物科技有限公司 一种多肽衍生物的合成方法
JP7196087B2 (ja) * 2017-10-03 2022-12-26 日産化学株式会社 ペプチド化合物の製造方法
CA3133805A1 (en) * 2019-03-15 2020-09-24 Nissan Chemical Corporation Method for producing peptide compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827083D0 (en) * 1988-11-19 1988-12-21 Porton Prod Ltd Trialkylsilyl esters of amino acids & their use in synthesis of peptides
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
JP4328202B2 (ja) * 2001-08-31 2009-09-09 ビーティージー・インターナショナル・リミテッド 抗癌シクロペンタ［ｇ］キナゾリン化合物
ES2373644T3 (es) * 2001-08-31 2012-02-07 Btg International Limited Uso de derivados de ciclopenta[g]quinazolina para el tratamiento del c�?ncer.
ATE421322T1 (de) * 2003-04-04 2009-02-15 Novartis Pharma Gmbh Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
ES2387334T3 (es) * 2008-03-18 2012-09-20 Btg International Limited Derivados de ciclopenta[g]quinazolina para el tratamiento de la artritis reumatoide o la leucemia mielocítica aguda

Also Published As

Publication number Publication date
EA201390635A1 (ru) 2014-09-30
US9458188B2 (en) 2016-10-04
CN103748106A (zh) 2014-04-23
WO2012087888A2 (en) 2012-06-28
KR20130132481A (ko) 2013-12-04
CA2819510A1 (en) 2012-06-28
EP2655398A4 (en) 2015-06-17
BR112013015600A2 (pt) 2018-05-22
IL226452A0 (en) 2013-07-31
SG191269A1 (en) 2013-07-31
DK2655398T3 (en) 2016-09-26
WO2012087888A3 (en) 2014-03-06
EP2655398B1 (en) 2016-08-24
MX2013007006A (es) 2013-07-30
EP2655398A2 (en) 2013-10-30
JP2014513663A (ja) 2014-06-05
US20130345423A1 (en) 2013-12-26
ZA201303821B (en) 2014-04-30
HUE028918T2 (en) 2017-01-30
AU2011349551A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CO6721028A2 (es) Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina
BRPI0923728A2 (pt) "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase".
UA115320C2 (uk) Інгібітори кінази
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
PE20141406A1 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
HRP20191295T8 (hr) Kristalne soli amida (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksilne kiseline i postupci uporabe istih
MY167216A (en) Kinase inhibitors
BR112014009084A2 (pt) polimorfos de arry-380, inibidor seletivo de herb2 e composições farmacêuticas que contenham os mesmos
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
UY34191A (es) ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?.
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
UY34647A (es) Composiciones farmacéuticas
CR20110082A (es) Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение
BRPI0916895A2 (pt) uso de lisina, arginina e outros compostos aminados, produto e administração de dosagem de produto
EA201000720A1 (ru) 4,4-дизамещённые пиперидины как ингибиторы ренина